Osimertinib plus Ramucirumab: The Best of Both Worlds?

ABSTRACT: Both osimertinib and the combination of erlotinib plus ramucirumab are approved for initial therapy of advanced EGFR mutation-positive non-small cell lung cancer. Osimertinib is also approved in previously treated T790M mutation-positive patients. The accompanying article reports on a study combining osimertinib with ramucirumab.See related article by Yu et al., p. 992.

SUBMITTER: Garon EB 

PROVIDER: S-EPMC7887048 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature